126 related articles for article (PubMed ID: 6428017)
41. [Cytoplasmic estrogen and progestin receptors in uterine myomatous tissue and serum estradiol and progesterone levels in women with uterine myoma].
Chen GA
Zhonghua Fu Chan Ke Za Zhi; 1984 Apr; 19(2):88-92. PubMed ID: 6468092
[No Abstract] [Full Text] [Related]
42. [Effect of the steroid sex hormones on the LH and FSH responses to LHRH in the normal subject].
Lemarchand-Béraud T; Reymond M; Rappoport G; Magrini G; Gomez J
Pathol Biol (Paris); 1975 Dec; 23(10):917-22. PubMed ID: 772543
[TBL] [Abstract][Full Text] [Related]
43. Hormone receptor status of a contralateral breast cancer is independent of the receptor status of the first primary in patients not receiving adjuvant tamoxifen.
Arpino G; Weiss HL; Clark GM; Hilsenbeck SG; Osborne CK
J Clin Oncol; 2005 Jul; 23(21):4687-94. PubMed ID: 15837971
[TBL] [Abstract][Full Text] [Related]
44. Plasma hormones and pituitary luteinizing hormone in the rat during the early stages of pregnancy and after post-coital treatment with tamoxifen (ICI 46,474).
Watson J; Anderson FB; Alam M; O'Grady JE; Heald PJ
J Endocrinol; 1975 Apr; 65(1):7-17. PubMed ID: 1141814
[TBL] [Abstract][Full Text] [Related]
45. Temporal relationships between ovulation and defined changes in the concentration of plasma estradiol-17 beta, luteinizing hormone, follicle-stimulating hormone, and progesterone. I. Probit analysis. World Health Organization, Task Force on Methods for the Determination of the Fertile Period, Special Programme of Research, Development and Research Training in Human Reproduction.
Am J Obstet Gynecol; 1980 Oct; 138(4):383-90. PubMed ID: 6775535
[TBL] [Abstract][Full Text] [Related]
46. Peptide and steroid hormone levels in pre- and postmenopausal breast carcinoma.
Bhatavdekar JM; Shah NG; Trivedi SN; Karelia NH
Neoplasma; 1987; 34(1):95-9. PubMed ID: 3104809
[TBL] [Abstract][Full Text] [Related]
47. Tamoxifen as a possible chemotherapeutic agent in endometrial adenocarcinoma.
Bonte J; Ide P; Billiet G; Wynants P
Gynecol Oncol; 1981 Apr; 11(2):140-61. PubMed ID: 6783481
[No Abstract] [Full Text] [Related]
48. [Histopathological changes in endometrial cancer treated with tamoxifen].
Lin HH; Ueda K; Kato J
Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 1):1038-43. PubMed ID: 3963849
[TBL] [Abstract][Full Text] [Related]
49. [Endometrial cancer and steroid hormone receptors].
Nyholm HC
Ugeskr Laeger; 1990 Feb; 152(9):593-7. PubMed ID: 2408223
[TBL] [Abstract][Full Text] [Related]
50. Phase II study of vorozole (R83842), a new aromatase inhibitor, in postmenopausal women with advanced breast cancer in progression on tamoxifen.
Goss PE; Clark RM; Ambus U; Weizel HA; Wadden NA; Crump M; Walde D; Tye LM; De Coster R; Bruynseels J
Clin Cancer Res; 1995 Mar; 1(3):287-94. PubMed ID: 9815984
[TBL] [Abstract][Full Text] [Related]
51. Effect of tamoxifen on steroid hormone receptors and creatine kinase activity in human endometrial carcinoma.
Iacobelli S; Scambia G; Atlante G; Landoni F; Sismondi P; Vecchio FM
Eur J Cancer Clin Oncol; 1986 Jan; 22(1):105-10. PubMed ID: 3956553
[TBL] [Abstract][Full Text] [Related]
52. Correlation between climacteric symptoms and serum levels of estradiol, progesterone, follicle-stimulating hormone, and luteinizing hormone.
Abe T; Furuhashi N; Yamaya Y; Wada Y; Hoshiai A; Suzuki M
Am J Obstet Gynecol; 1977 Sep; 129(1):65-7. PubMed ID: 900171
[TBL] [Abstract][Full Text] [Related]
53. Endocrine status of premenopausal node-positive breast cancer patients following adjuvant chemotherapy and long-term tamoxifen.
Ravdin PM; Fritz NF; Tormey DC; Jordan VC
Cancer Res; 1988 Feb; 48(4):1026-9. PubMed ID: 3123050
[TBL] [Abstract][Full Text] [Related]
54. Endocrine consequences of continuous antiestrogen therapy with tamoxifen in premenopausal women.
Sherman BM; Chapler FK; Crickard K; Wycoff D
J Clin Invest; 1979 Aug; 64(2):398-404. PubMed ID: 110834
[TBL] [Abstract][Full Text] [Related]
55. Quantitative oestrogen and progesterone receptor values in primary breast cancer and predictability of response to endocrine therapy.
Fernandez MD; Alaghband-Zadeh J; Burn JI
Clin Oncol; 1983 Sep; 9(3):245-50. PubMed ID: 6616999
[TBL] [Abstract][Full Text] [Related]
56. Efficacy of sequential cyclical hormonal therapy in endometrial cancer and its correlation with steroid hormone receptor status.
Ayoub J; Audet-Lapointe P; Méthot Y; Hanley J; Beaulieu R; Chemaly R; Cormier A; Déry JP; Drouin P; Gauthier P
Gynecol Oncol; 1988 Oct; 31(2):327-37. PubMed ID: 2971597
[TBL] [Abstract][Full Text] [Related]
57. Endometrial histology and circulating levels of medroxyprogesterone acetate (MPA), estradiol, FSH and LH in women with MPA induced amenorrhoea compared with women with secondary amenorrhoea.
Jeppsson S; Johansson ED; Ljungberg O; Sjöberg NO
Acta Obstet Gynecol Scand; 1977; 56(1):43-8. PubMed ID: 842303
[TBL] [Abstract][Full Text] [Related]
58. Androgen, estrogen, and progesterone receptor contents and serum hormone profiles in patients with benign hypertrophy and carcinoma of the prostate.
Kumar VL; Wadhwa SN; Kumar V; Farooq A
J Surg Oncol; 1990 Jun; 44(2):122-8. PubMed ID: 1693995
[TBL] [Abstract][Full Text] [Related]
59. Estrogen receptors and blood hormone levels in endometrial carcinoma.
Hähnel R; Martin JD; Masters AM; Ratajczak T; Twaddle E
Gynecol Oncol; 1979 Oct; 8(2):209-25. PubMed ID: 387546
[No Abstract] [Full Text] [Related]
60. [Treatment of marked gynecomastia in puberty with tamoxifen].
König R; Schönberger W; Neumann P; Benes P; Grimm W
Klin Padiatr; 1987; 199(6):389-91. PubMed ID: 3123765
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
